John J Suschak

List of Publications by Year
in descending order

21	731	686830 13	794141 19
papers	citations	h-index	g-index

21	21	21	1262
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A DNA vaccine targeting VEE virus delivered by needle-free jet-injection protects macaques against aerosol challenge. Npj Vaccines, 2022, 7, 46.	2.9	9
2	A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice. Npj Vaccines, 2021, 6, 31.	2.9	25
3	Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge. Vaccines, 2021, 9, 881.	2.1	86
4	Nanoplasmid Vectors Co-expressing Innate Immune Agonists Enhance DNA Vaccines for Venezuelan Equine Encephalitis Virus and Ebola Virus. Molecular Therapy - Methods and Clinical Development, 2020, 17, 810-821.	1.8	20
5	Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates. Human Vaccines and Immunotherapeutics, 2019, 15, 2359-2377.	1.4	31
6	Future Approaches to DNA Vaccination Against Hemorrhagic Fever Viruses. Methods in Molecular Biology, 2018, 1604, 339-348.	0.4	1
7	The genetic adjuvant IL-12 enhances the protective efficacy of a DNA vaccine for Venezuelan equine encephalitis virus delivered by intramuscular injection in mice. Antiviral Research, 2018, 159, 113-121.	1.9	8
8	The Genetic Adjuvants Interleukin-12 and Granulocyte-Macrophage Colony Stimulating Factor Enhance the Immunogenicity of an Ebola Virus Deoxyribonucleic Acid Vaccine in Mice. Journal of Infectious Diseases, 2018, 218, S519-S527.	1.9	8
9	An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice. Human Vaccines and Immunotherapeutics, 2017, 13, 2824-2836.	1.4	21
10	Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity. Human Vaccines and Immunotherapeutics, 2017, 13, 2837-2848.	1.4	168
11	A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models. PLoS Neglected Tropical Diseases, 2017, 11, e0005908.	1.3	76
12	A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines. Journal of Immunology, 2016, 196, 310-316.	0.4	72
13	Identification of Aim2 as a Sensor for DNA Vaccines. Journal of Immunology, 2015, 194, 630-636.	0.4	47
14	Molecular methods for evaluation of virological status of nonhuman primates challenged with simian immunodeficiency or simian-human immunodeficiency viruses. Journal of Virological Methods, 2010, 163, 287-294.	1.0	39
15	Characterization of a SHIV162P3 variant evolved in an infected rhesus macaque with persistent plasma viremia. Virus Research, 2010, 151, 229-234.	1.1	5
16	P11-21. Induction of persistent mucosal humoral and cellular responses following immunization of mice with HIV-1 envelope protein in inulin-derived adjuvants. Retrovirology, 2009, 6, .	0.9	0
17	P03-10. Induction of neutralizing antibodies in Rhesus macaques following mucosal challenge with R5 tropic SHIV162P3 isolate. Retrovirology, 2009, 6, .	0.9	0
18	Differential pathogenicity of SHIV_{SF162 P4} infection in pigâ€tailed and rhesus macaques. Journal of Medical Primatology, 2008, 37, 13-23.	0.3	28

#	Article	IF	Citations
19	Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation. Biochemical and Biophysical Research Communications, 2008, 366, 29-35.	1.0	36
20	HIV-1 Env vaccine comprised of electroporated DNA and protein co-administered with Talabostat. Biochemical and Biophysical Research Communications, 2008, 370, 22-26.	1.0	10
21	HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology, 2007, 366, 197-211.	1.1	41